AU2013207585A1 - Melatonin agonist treatment - Google Patents

Melatonin agonist treatment

Info

Publication number
AU2013207585A1
AU2013207585A1 AU2013207585A AU2013207585A AU2013207585A1 AU 2013207585 A1 AU2013207585 A1 AU 2013207585A1 AU 2013207585 A AU2013207585 A AU 2013207585A AU 2013207585 A AU2013207585 A AU 2013207585A AU 2013207585 A1 AU2013207585 A1 AU 2013207585A1
Authority
AU
Australia
Prior art keywords
agonist treatment
melatonin agonist
melatonin
treatment
agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU2013207585A
Other versions
AU2013207585B2 (en
Inventor
Gunther Birznieks
Deepak Phadke
Mihael H. Polymeropoulos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanda Pharmaceuticals Inc
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2007253701A external-priority patent/AU2007253701A1/en
Priority to AU2013207585A priority Critical patent/AU2013207585B2/en
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Publication of AU2013207585A1 publication Critical patent/AU2013207585A1/en
Priority to AU2016202001A priority patent/AU2016202001A1/en
Publication of AU2013207585B2 publication Critical patent/AU2013207585B2/en
Application granted granted Critical
Assigned to VANDA PHARMACEUTICALS, INC. reassignment VANDA PHARMACEUTICALS, INC. Amend patent request/document other than specification (104) Assignors: VANDA PHARMACEUTICALS, INC
Priority to AU2018201219A priority patent/AU2018201219A1/en
Priority to AU2019250266A priority patent/AU2019250266A1/en
Priority to AU2021273588A priority patent/AU2021273588B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

AU2013207585A 2006-05-22 2013-07-17 Melatonin agonist treatment Active AU2013207585B2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2013207585A AU2013207585B2 (en) 2006-05-22 2013-07-17 Melatonin agonist treatment
AU2016202001A AU2016202001A1 (en) 2006-05-22 2016-03-31 Melatonin agonist treatment
AU2018201219A AU2018201219A1 (en) 2006-05-22 2018-02-20 Melatonin agonist treatment
AU2019250266A AU2019250266A1 (en) 2006-05-22 2019-10-18 Melatonin agonist treatment
AU2021273588A AU2021273588B2 (en) 2006-05-22 2021-11-24 Melatonin agonist treatment

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US74784706P 2006-05-22 2006-05-22
US60/747,847 2006-05-22
AU2007253701A AU2007253701A1 (en) 2006-05-22 2007-05-22 Melatonin agonist treatment
AU2013207585A AU2013207585B2 (en) 2006-05-22 2013-07-17 Melatonin agonist treatment

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
AU2007253701A Division AU2007253701A1 (en) 2006-05-22 2007-05-22 Melatonin agonist treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2016202001A Division AU2016202001A1 (en) 2006-05-22 2016-03-31 Melatonin agonist treatment

Publications (2)

Publication Number Publication Date
AU2013207585A1 true AU2013207585A1 (en) 2013-08-08
AU2013207585B2 AU2013207585B2 (en) 2016-04-28

Family

ID=38723632

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2007253701A Abandoned AU2007253701A1 (en) 2006-05-22 2007-05-22 Melatonin agonist treatment
AU2013207585A Active AU2013207585B2 (en) 2006-05-22 2013-07-17 Melatonin agonist treatment
AU2021273588A Active AU2021273588B2 (en) 2006-05-22 2021-11-24 Melatonin agonist treatment

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU2007253701A Abandoned AU2007253701A1 (en) 2006-05-22 2007-05-22 Melatonin agonist treatment

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021273588A Active AU2021273588B2 (en) 2006-05-22 2021-11-24 Melatonin agonist treatment

Country Status (17)

Country Link
US (6) US20090105333A1 (en)
EP (1) EP2028937B2 (en)
JP (5) JP2009538332A (en)
KR (2) KR101571163B1 (en)
AU (3) AU2007253701A1 (en)
BR (1) BRPI0712206A2 (en)
CA (2) CA2666293C (en)
CY (1) CY1120433T1 (en)
DK (1) DK2028937T4 (en)
ES (1) ES2532849T5 (en)
MX (1) MX2008014841A (en)
NL (1) NL300795I2 (en)
PL (1) PL2028937T5 (en)
PT (1) PT2028937E (en)
RU (1) RU2488392C2 (en)
WO (1) WO2007137244A1 (en)
ZA (1) ZA200809529B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2028937T4 (en) † 2006-05-22 2018-09-03 Vanda Pharmaceuticals Inc Treatment with melatonin agonists
CA2698540A1 (en) * 2007-09-13 2009-03-19 Vanda Pharmaceuticals, Inc. Prediction of sleep parameter and response to sleep-inducing compound based on per3 vntr genotype
EP2453891A1 (en) * 2009-07-16 2012-05-23 Vanda Pharmaceuticals Inc. Use of a melatonin agonist for the treatment of sleep disorders including primary insomnia
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
KR102307012B1 (en) * 2012-01-26 2021-09-30 반다 파마슈티칼즈, 인코퍼레이티드. Treatment of circadian rhythm disorders
JP6144358B2 (en) * 2012-12-18 2017-06-07 ヴァンダ ファーマシューティカルズ インコーポレイテッド Treatment of circadian rhythm disorders
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
WO2015117048A1 (en) 2014-01-31 2015-08-06 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
CA2957588C (en) 2014-09-02 2021-08-31 Vanda Pharmaceuticals Inc. Tasimelteon for treating smith-magenis syndrome
EP3661494B8 (en) 2017-08-02 2023-11-22 Vanda Pharmaceuticals Inc. Use of tasimelteon for the treatment of affective disorders in majority black african patients
BR112020017886A2 (en) * 2018-03-04 2021-03-23 Vanda Pharmaceuticals Inc. methods to treat an individual experiencing an advance in interrupting the sleep-wake cycle at the individual's established bedtime, to treat jet lag in an individual and to reduce an unwanted consequence of up to eight hours' advance in an established bedtime individual, and prepackaged dispensing unit
JP7432884B2 (en) * 2018-03-26 2024-02-19 パナソニックＩｐマネジメント株式会社 Support system, device control system, method of operating the support system, and method of operating the device control system
SG11202101828PA (en) 2018-09-12 2021-04-29 Vanda Pharmaceuticals Inc Improving sleep or post-sleep performance
EP4186502A1 (en) * 2019-02-13 2023-05-31 Vanda Pharmaceuticals Inc. Method of improving sleep
KR20220027977A (en) * 2019-06-29 2022-03-08 반다 파마슈티칼즈, 인코퍼레이티드. Use of tasimelteon in the treatment of sleep disorders
CN114727978A (en) 2019-12-13 2022-07-08 万达制药公司 Liquid tasimelteon formulations and methods of use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3466215D1 (en) * 1983-05-18 1987-10-22 Univ Monash The use of melatonin for the manufacture of a medicament
US5242941A (en) † 1990-12-04 1993-09-07 State Of Oregon Methods of treating circadian rhythm disorders
IT1251544B (en) * 1991-05-13 1995-05-17 Gabriele Biella PHARMACEUTICAL COMPOSITIONS ACTIVE IN THE THERAPY OF SLEEP DISORDERS INCLUDING MELATONIN OR A DERIVATIVE IN ASSOCIATION WITH A BENZODIAZEPINE DERIVATIVE
GB9416884D0 (en) * 1994-08-20 1994-10-12 Danbiosyst Uk Drug delivery compositions
RU2188006C2 (en) * 1995-03-06 2002-08-27 Ново Нордиск А/С Stimulation of meiosis
KR100499106B1 (en) * 1996-12-10 2005-07-01 브리스톨-마이어즈 스퀴브 컴페니 Benzodioxole, benzofuran, dihydrobenzofuran, and benzodioxane melatonergic agents
US5776969A (en) * 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders
WO2005063240A1 (en) * 2003-12-22 2005-07-14 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of hypertension
EP1696959A2 (en) * 2003-12-24 2006-09-06 Sepracor, Inc. Melatonin combination therapy for improving sleep quality
WO2007016203A1 (en) * 2005-07-29 2007-02-08 Vanda Pharmaceuticals, Inc. Method of improving wakefulness
DK2028937T4 (en) † 2006-05-22 2018-09-03 Vanda Pharmaceuticals Inc Treatment with melatonin agonists
KR102307012B1 (en) * 2012-01-26 2021-09-30 반다 파마슈티칼즈, 인코퍼레이티드. Treatment of circadian rhythm disorders
US10376487B2 (en) * 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
EP3105212A1 (en) * 2014-02-12 2016-12-21 Vanda Pharmaceuticals Inc. Highly purified pharmaceutical grade tasimelteon
WO2016066631A1 (en) † 2014-10-28 2016-05-06 Sandoz Ag Pharmaceutical composition consisting of ceftaroline fosamil acetic acid solvate particles and arginine particles, both having a specific particle size distribution

Similar Documents

Publication Publication Date Title
AU2013207585A1 (en) Melatonin agonist treatment
ZA200809529B (en) Melatonin agonist treatment
EP1989185B8 (en) Therapeutic compounds
WO2007082127A8 (en) Combination therapy for long-lasting ckrtm
EP2047792B8 (en) Endoscope apparatus
GB0624874D0 (en) Treatment
GB0600692D0 (en) Well treatment
AU2008263581A8 (en) Well treatment
GB0604460D0 (en) Treatment
AU2012101548A4 (en) Water Treatment Apparatus
AU2006905623A0 (en) Treatment
AU2007901118A0 (en) Treatment methods
AU2006903094A0 (en) Diathermy device
AU2006903536A0 (en) Apparatus
AU2006904965A0 (en) Apparatus
AU2006905320A0 (en) Patient Turning Apparatus
AU2006902723A0 (en) Therapeutic treatment
AU2007903788A0 (en) Biofilm treatment
AU2006902715A0 (en) Compounds and Methods
GB0610431D0 (en) Treatment
GB0605781D0 (en) Treatment
AU2006900405A0 (en) Treatment process
AU2006901263A0 (en) Portable fishing apparatus
AU2008903020A0 (en) Treatment
AU2006903625A0 (en) Therapeutic compounds